Apalutamide Plus ADT Leads to Survival Benefit in mCSPC
Neeraj Agarwal, MD, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy plus the novel androgen receptor inhibitor apalutamide or ADT alone.
Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy (ADT) plus the novel androgen receptor inhibitor apalutamide (Erleada) or ADT alone.
The study included 2 coprimary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS). The apalutamide combination was superior to ADT alone for both endpoints, Agarwal says. There was a 52% reduction in the risk of radiographic disease progression and a 37% reduction in the risk of death. There was also an impressive improvement in OS, Agarwal notes
The results from the TITAN trial ultimately led to theFDA’s approval of apalutamide for patients with metastatic castration-sensitive prostate cancer
